California-based biotechnology firm Integrated Biosciences has partnered with Illumina Ventures Labs to unite Integrated Biosciences’ drug discovery technology with Illumina's sequencing capabilities. The terms and financial details of the agreement have not been disclosed.

Under the collaboration, Integrated Biosciences plans to develop new kinds of small-molecule therapeutics that alter cell behavior with scientific and monetary support from Illumina. These candidates will target various diseases related to aging and development. Integrated Biosciences claims that this collaboration will help generate large-scale datasets that detail modifying cellular components such as nucleic acids to develop novel treatments.

Integrated Biosciences leverages synthetic biology and ML to control cellular stress responses, enabling the discovery of treatments for diseases such as cancer, diabetes, and osteoarthritis. The company’s pipeline includes several clinical-stage programs varying between modulating aging cells and cellular stress and protecting against cellular damage, among others.